Phase I/II Study of Obatoclax Mesylate (GX15-070MS), a Bcl-2 Antagonist, Plus Topotecan in Relapsed Small Cell Lung Carcinoma.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Obatoclax (Primary) ; Topotecan
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 28 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Sep 2007 New trial record.